Temozolomide in Patients with Advanced Cancer: Phase I and Pharmacokinetic Study

Study Objective. To determine the maximum tolerated dose, dose‐limiting toxicity, pharmacokinetics, and potential antitumor activity of temozolomide administered as a single dose every 28 days.

[1]  Sudhakar M. Pai,et al.  Population Pharmacokinetics of Temozolomide in Cancer Patients , 2000, Pharmaceutical Research.

[2]  J. Raizer,et al.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. , 2002, Neuro-oncology.

[3]  A. Nomeir,et al.  High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. , 2001, Journal of pharmaceutical and biomedical analysis.

[4]  H. Friedman,et al.  Temozolomide and treatment of malignant glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  G. Weiss,et al.  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Grochow,et al.  Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Rustin,et al.  O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. , 1998, British Journal of Cancer.

[8]  M. Roddie,et al.  Phase I trial of temozolomide using an extended continuous oral schedule. , 1998, Cancer research.

[9]  J. Reid,et al.  Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Buckner,et al.  Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  N. Bleehen,et al.  Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma , 1997, Cancer Chemotherapy and Pharmacology.

[12]  E. Newlands,et al.  The Charing Cross Hospital experience with temozolomide in patients with gliomas. , 1996, European journal of cancer.

[13]  S. Markowitz,et al.  Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. , 1996, Cancer research.

[14]  E. Newlands,et al.  3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. , 1996, British Journal of Cancer.

[15]  E. Newlands,et al.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. , 1996, British Journal of Cancer.

[16]  D. Crowther,et al.  Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. , 1995, British Journal of Cancer.

[17]  N. Bleehen,et al.  Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Stevens,et al.  NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. , 1994, Biochemistry.

[19]  C. Kennard,et al.  Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.

[20]  E. Newlands,et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.

[21]  M. Dolan,et al.  Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. , 1991, Cancer research.

[22]  S P Langdon,et al.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.

[23]  L. Bauer.  Biopharmaceutics and clinical pharmacokinetics, 4th edition , 1987 .

[24]  W. Mattes,et al.  DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. , 1986, Cancer research.

[25]  J. Hickman,et al.  DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one. , 1984, Cancer research.

[26]  M. Gibaldi,et al.  Noncompartmental Analysis Based on Statistical Moment Theory , 1982 .

[27]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[28]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.